Who We Are
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple modalities. The pipeline includes these investigational product candidates:
- ONCT-808, an autologous CAR T cell therapy that targets ROR1, as a targeted therapy for patients with multiple hematologic and solid malignancies.
- ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI), as a targeted therapy for patients with advanced prostate cancer resistant to available therapies.
- Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein that is highly expressed in multiple hematologic and solid malignancies.
On September 12, 2024, Oncternal announced it was discontinuing its clinical trials and exploring strategic alternatives.
